News | EP Mapping and Imaging Systems | October 29, 2018

First Carto Vizigo Bi-Directional Guiding Sheath Employed on West Coast

Sheath can be visualized on Carto 3 system during catheter ablation to reduce dependence on fluoroscopy

First Carto Vizigo Bi-Directional Guiding Sheath Employed on West Coast

October 29, 2018 — Good Samaritan Hospital recently became the first hospital on the West Coast to utilize the Carto Vizigo bi-directional guiding sheath. The sheath can be visualized on the Carto 3 System during a catheter ablation procedure, helping electrophysiologists reduce dependency on fluoroscopy.

A sheath is an introducer routinely used by physicians to facilitate catheter access, stability and tissue contact when targeting sites for catheter ablation to treat arrhythmias. Electrophysiologists rely on fluoroscopy to identify the location of the sheath, therefore requiring use of lead to protect themselves from radiation during the procedure.

According to Ivan Ho, M.D., electrophysiologist practicing at Good Samaritan Hospital and the first to use the technology on the West Coast, the long deflectable sheath has become a major step forward in achieving catheter stability and appropriate radiofrequency energy delivery in complex left-sided arrhythmia ablations. "One of the limitations has been the need of periodic fluoroscopic imaging of the sheath's relative position with the catheter to optimize contact with endocardial surface and ensure safety due to the relatively stiff shaft of these sheaths," said Ho.  The Vizigo allows the direction of the sheath and its relationship with the catheter to be visualized accurately on a 3-D mapping system, minimizing the use of fluoroscopy and overall procedure time.

This new technology is incorporated easily into the physicians' workflow, designed to enhance efficiency during mapping and positioning of the ablation catheter. The smooth tip-to-dilator transition promotes ease of entry into the left atrium during transseptal access, while deflections of 180 degrees in both directions mean increased steerability, which may improve access to hard-to-reach sites.

For more information: www.biosensewebster.com


Related Content

News

April 26, 2026 — New results from the multicenter catheter ablation versus anti-arrhythmic drugs for Ventricular ...

Home April 29, 2026
Home
News

April 24, 2026 — Johnson & Johnson recently announced the initiation of the PERSIGMA randomized controlled trial (RCT) ...

Home April 27, 2026
Home
News

April 26, 2026 – New results from the pivotal multicenter trial FULCRUM-VT show that ultra-low temperature ablation ...

Home April 27, 2026
Home
News

April 13, 2026 — Johnson & Johnson has announced favorable 12-month interim effectiveness and safety results from ...

Home April 13, 2026
Home
News

In a milestone for Broward Health in Ft. Lauderdale, Fla., Jose L. Baez-Escudero, M.D., chief of cardiology and ...

Home March 24, 2026
Home
News

Feb. 6, 2026 — Abbott has announced new clinical data from two late-breaking presentations at AF Symposium in Boston ...

Home February 06, 2026
Home
News

Jan. 20, 2026 — Abbott has received CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat ...

Home January 22, 2026
Home
News

Jan. 20, 2026 — Kardium Inc. has announced the publication of the PULSAR clinical trial results in the Journal of the ...

Home January 21, 2026
Home
Feature | Kyle Hardner

Robotic Magnetic Navigation (RMN) emerged two decades ago as an alternative approach to performing complex ablation ...

Home January 09, 2026
Home
News

Jan. 6, 2026 — Stereotaxis, a supplier of surgical robotics for minimally invasive endovascular intervention, has ...

Home January 06, 2026
Home
Subscribe Now